NDA 211962 · Hikma
Tyzavan
Vancomycin Hydrochloride · Intravenous · Glycopeptide Antibacterial
Priority reviewLast checked: Nov 20, 2026Latest source record: Aug 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Feb 15, 2019
Approved uses
3
Original approval plus efficacy supplements
Registered trials
501
123 Phase 3, 64 recruiting
FAERS reports
58,342
53,932 serious, 11,489 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 19, 2026.
TYZAVAN is a glycopeptide antibacterial indicated for the treatment of the following infections in adult and pediatric patients (1 month and older) for whom appropriate dosing with this formulation can be achieved: Septicemia ( 1.1 ) Infective Endocarditis ( 1.2 ) Skin and Skin Structure Infections ( 1.3 ) Bone Infections ( 1.4 ) Lower Respiratory Tract Infections ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYZAVAN and other antibacterial drugs, TYZAVAN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Septicemia TYZAVAN is indicated in adults and pediatric patients (1 month and older) for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration (2) and Use in Specific Populations (8.4) ] for the treatment of septicemia due to: Susceptible isolates of methicillin-resistant Staphylococcus aureus (MRSA) and coagulase negative staphylococci. Methicillin-susceptible staphylococci in penicillin-allergic patients, or those patients who cannot receive or who have failed to respond to other drugs, including penicillins or cephalosporins. 1.2 Infective Endocarditis TYZAVAN is indicated in adults and pediatric patients (1 month and older) for whom appropriate dosing with this formulation can be achieved [see Dosage and Administration (2) and Use in Specific Populations (8.4) ] for the treatment of infective endocarditis due to: Susceptible isolates of MRSA. Viridans group streptococci Streptococcus gallolyticus (previously known as Streptococcus bovis ), Enterococcus species and Corynebacterium species. For enterococcal endocarditis, use TYZAVAN in combination with an aminoglycoside. Methicillin-susceptible...
Mechanism: Vancomycin is an antibacterial drug [see Microbiology (12.4) ] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 27, 2025 Supplement 17 · Efficacy LetterLabel
- May 28, 2021 Supplement 9 · Efficacy LetterLabel
- Feb 15, 2019 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LabelLetterReview
7 products under this application
- TYZAVAN · VANCOMYCIN HYDROCHLORIDE EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
- TYZAVAN · VANCOMYCIN HYDROCHLORIDE EQ 2GM BASE/400ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
- TYZAVAN · VANCOMYCIN HYDROCHLORIDE EQ 1GM BASE/200ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
- TYZAVAN · VANCOMYCIN HYDROCHLORIDE EQ 1.75GM BASE/350ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
- TYZAVAN · VANCOMYCIN HYDROCHLORIDE EQ 750MG BASE/150ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
- TYZAVAN · VANCOMYCIN HYDROCHLORIDE EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
- TYZAVAN · VANCOMYCIN HYDROCHLORIDE EQ 500MG BASE/100ML (EQ 5MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Vancomycin" as an intervention, any sponsor and status, largest first.
- Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over TrialPivotal-lookingNot yet recruiting
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT06567808 · 38,000 participants (planned) · Start Mar 1, 2026 · Primary completion Apr 30, 2028
Drug: Cefazolin; Vancomycin · For: Infection, Surgical Site
VA Office of Research and DevelopmentFederal agency
NCT02216227 · 23,005 participants · Start Apr 1, 2014 · Primary completion Feb 28, 2021
Drug: Mupirocin; Chlorhexidine gluconate and 3 more · For: Surgical Site Infection
Sites: Miami, Florida; Iowa City, Iowa; Baltimore, Maryland · 11 sites in all
- Infection Prophylaxis in Total Joint ReplacementPivotal-lookingRecruiting
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT06126614 · 21,006 participants (planned) · Start May 7, 2024 · Primary completion Nov 2028
Drug: Chlorhexidine Gluconate; Vancomycin Hydrochloride · For: Periprosthetic Joint Infection
Sites: Hamilton, Canada
- Prevention of Arrhythmia Device Infection Trial (PADIT)Pivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT01628666 · 12,814 participants · Start Dec 2012 · Primary completion Sep 8, 2017
Drug: Incremental; Conventional · For: Arrhythmia
Sites: Hamilton, Canada
- Staphylococcus Aureus Network Adaptive Platform TrialPivotal-lookingRecruiting
University of MelbourneAcademic, hospital or other
NCT05137119 · 8,000 participants (planned) · Start Feb 16, 2022 · Primary completion Dec 1, 2028
Drug: Cefazolin; Penicillin and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Houston, Texas; Garran, Australia; Blacktown, Australia · 161 sites in all
- Prevention of Infections in Cardiac SurgeryPivotal-lookingTerminated
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT02285140 · 5,989 participants · Start Apr 2015 · Primary completion Mar 10, 2025
Drug: Cefazolin; Vancomycin · For: Thoracic Surgery; Antibiotic Prophylaxis
Sites: Hamilton, Canada; Toronto, Canada; Montreal, Canada · 4 sites in all
- Prevention of Infections in Cardiac Surgery (PICS) Prevena StudyPivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT03402945 · 4,107 participants · Start Mar 5, 2018 · Primary completion Apr 27, 2023
Drug: Cefazolin; Vancomycin · For: Surgical Site Infections
Sites: Hamilton, Canada; London, Canada
- Simplified Selective Digestive Tract Decontamination for the Prevention of Intensive Care Unit Acquired InfectionsPivotal-lookingStatus unknown
Rambam Health Care CampusAcademic, hospital or other
NCT01798537 · 2,400 participants (planned) · Start Jun 2013 · Primary completion Jul 2015
Drug: Neomycin Colistin Nystatin Vancomycin · For: Bacteremia Associated With Intravascular Line; Ventilator Associated Pneumonia; Bacteremia
Sites: Haifa, Israel
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective6,607
- acute kidney injury4,422
- off label use4,327
- pyrexia3,646
- drug reaction with eosinophilia and systemic symptoms2,411
- renal failure2,243
- diarrhoea2,123
- sepsis2,115
- condition aggravated1,970
- pneumonia1,959
- hypotension1,948
- rash1,882
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 798 |
| 2005 | 863 |
| 2006 | 930 |
| 2007 | 720 |
| 2008 | 847 |
| 2009 | 931 |
| 2010 | 1,241 |
| 2011 | 1,805 |
| 2012 | 1,749 |
| 2013 | 1,667 |
| 2014 | 1,787 |
| 2015 | 2,199 |
| 2016 | 2,602 |
| 2017 | 3,174 |
| 2018 | 4,303 |
| 2019 | 4,023 |
| 2020 | 4,815 |
| 2021 | 4,489 |
| 2022 | 3,937 |
| 2023 | 4,011 |
| 2024 | 4,398 |
| 2025 | 4,351 |
| 2026 | 2,698 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ, Miller MA, Mullane KM, et al. · N Engl J Med 2011 · Clinical Trial, Phase III, Comparative Study
- Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus.
Kato H, Hagihara M, Asai N, et al. · J Glob Antimicrob Resist 2021 · Meta-Analysis, Systematic Review
- Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis.
Eichel VM, Last K, Brühwasser C, et al. · J Hosp Infect 2023 · Meta-Analysis, Systematic Review
- Risk factors for vancomycin-associated acute kidney injury: A systematic review and meta-analysis.
Kim JY, Yee J, Yoon HY, et al. · Br J Clin Pharmacol 2022 · Meta-Analysis, Systematic Review
- Fecal Microbiota Transplantation Versus Vancomycin for Primary Clostridioides difficile Infection : A Randomized Controlled Trial.
Juul FE, Bretthauer M, Johnsen PH, et al. · Ann Intern Med 2025 · Equivalence Trial, Multicenter Study
- Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta-analysis.
Abdelmessih E, Patel N, Vekaria J, et al. · Pharmacotherapy 2022 · Meta-Analysis, Research Support, N.I.H., Extramural
Sponsor: Hikma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.